Is Mounjaro Safer Than Ozempic? What the Evidence Actually Says

What the trial evidence tells us about side-effect profiles

A question our prescribers hear most weeks is whether one of these medicines is meaningfully safer than the other. The honest answer from the data is: they share a closely related side-effect profile, because both work on the GLP-1 receptor system.

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. Mounjaro's active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed in the UK. Both slow gastric emptying, reduce appetite and affect blood-sugar regulation through overlapping pathways. Because that mechanism is shared, so is much of the tolerability picture: nausea, vomiting, diarrhoea, constipation and indigestion are the most commonly reported effects with either medicine, typically peaking after a dose increase and settling over days to a couple of weeks, as documented on the NHS tirzepatide medicines page and its semaglutide equivalent.

In SURMOUNT-1, the pivotal tirzepatide weight-management trial published in the New England Journal of Medicine, gastrointestinal events were the most frequent reason for discontinuation but overall discontinuation rates were low. The semaglutide STEP 1 trial reported a broadly similar GI-led tolerability picture. Neither programme flagged a clear safety advantage for one over the other; the profiles are similar enough that the choice turns on clinical fit rather than a ranked safety verdict. You can read more about how semaglutide and tirzepatide compare on safety in more granular detail.

The UK licensing difference you need to know before asking 'which is safer?'

Ozempic is semaglutide, but it is licensed in the UK for type 2 diabetes, not for weight management. Using it for weight loss would be off-label. That matters for safety because off-label prescribing sits outside the formal monitoring framework that applies to a licensed indication, and it means the benefit-risk assessment published by the MHRA applies to a different patient group.

Wegovy is also semaglutide but holds a separate UK weight-management licence. It is the semaglutide product that should be part of any honest weight-loss safety comparison with Mounjaro. The Wegovy versus Mounjaro safety comparison is therefore the more clinically meaningful question for most people asking about weight loss. When readers ask 'is Ozempic safer than Mounjaro?' for weight purposes, the framing is understandable (the names circulate widely in the same conversations) but it conflates two products with different licensed populations.

The MHRA's guidance is clear that GLP-1 medicines are not assessed for cosmetic or quick weight loss, and the regulator has published explicit public information on this distinction. Any prescriber operating within UK law would direct a weight-management patient toward Mounjaro or Wegovy, not Ozempic. You can explore whether Mounjaro and Ozempic are the same medicine for a fuller explanation of what they share and where they differ.

Comparing Mounjaro and Ozempic: a factual summary

Sources: SURMOUNT-1, New England Journal of Medicine; NICE technology appraisal TA1026 (tirzepatide).

Which medicine is right for you? That is a clinical question, not a search result

Both medicines carry real risks alongside real benefits, and neither is appropriate for everyone. Pancreatitis is a known but infrequent serious risk with GLP-1 medicines generally; the MHRA has issued specific guidance that severe, persistent stomach pain radiating to the back warrants urgent medical attention. History of medullary thyroid carcinoma, certain GI conditions and a number of drug interactions all factor into whether either medicine is suitable. Pregnancy, breastfeeding and trying to conceive are reasons neither is recommended.

A prescriber does not rank medicines by a safety league table and pick the top one. They weigh your BMI, your existing conditions, your other medications and your history. The Ozempic and Mounjaro overview covers the shared background in more depth, and the Wegovy and Mounjaro comparison is the most relevant read for anyone exploring licensed weight-loss options side by side. Cost is another practical factor, how Wegovy and Mounjaro prices compare is a separate question worth understanding before you decide.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber who looks at your individual picture. They decide which medicine, at which starting point, is clinically appropriate for you. Which suits you is a clinical decision our prescribers make with you, speak to our prescribers through a free consultation to start that conversation.